Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRX to expedite clinical trials after opening state-of-the-art lab

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers
no_picture_pai.jpg
The facility was opened on time and within budget

VolitionRx Ltd (NYSEMKT:VNRX) has opened a new research and development facility in Belgium this week.

The US-listed European cancer diagnostics group said the purpose-built laboratory would enable it to increase capacity to carry out clinical trials and to expand its scientific team.

A more modern lab and a bigger lab team should lead to trials taking less time.

WATCH a video showcasing the start-of-the art lab

READ the VolitionRX investment case

"Our capacity to run large clinical trials has increased significantly with this five-fold increase in laboratory space. This will facilitate large scale manual and automated robotic testing. We will now have the ability to work on several large trials at the same time, namely: the front-line screening colorectal cancer tests and  lung, prostate and pancreatic cancer," said Dr Marielle Herzog, Research and Development Director of Volition.

Volition's Belgian arm acquired the 19,000 square foot property for €1.2mln – about US$1.29mln.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

View full VNRX profile View Profile

VolitionRx Timeline

Newswire
September 14 2017

Related Articles

picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use